Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sagar Lonial

Showing results (221-230 of 440) with videos related to

Pageof 44
Sort By:
Pharmacotherapy|February 5, 2022
Impact of concurrent gabapentin or pregabalin with high-dose melphalan in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplantAkhilesh Sivakumar, Evan B Bryson, Kevin H Hall, et al.
Leukemia|January 26, 2019
Functional profiling of venetoclax sensitivity can predict clinical response in multiple myelomaShannon M Matulis, Vikas A Gupta, Paola Neri, et al.
Leukemia & Lymphoma|February 1, 2012
Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myelomaJeffrey L Wolf, David Siegel, Hartmut Goldschmidt, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 15, 2013
Temporal changes in plerixafor administration and hematopoietic stem cell mobilization efficacy: results of a prospective clinical trial in multiple myelomaR Donald Harvey, Jonathan L Kaufman, Heather R Johnson, et al.
Cancer|October 18, 2018
Survival outcomes of patients with primary plasma cell leukemia (pPCL) treated with novel agentsRoberto Mina, Nisha S Joseph, Jonathan L Kaufman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 6, 2017
Ricolinostat, the First Selective Histone Deacetylase 6 Inhibitor, in Combination with Bortezomib and Dexamethasone for Relapsed or Refractory Multiple MyelomaDan T Vogl, Noopur Raje, Sundar Jagannath, et al.
Cancer Informatics|October 8, 2014
Integrated analysis of whole-genome paired-end and mate-pair sequencing data for identifying genomic structural variations in multiple myelomaRendong Yang, Li Chen, Scott Newman, et al.
Future Oncology (London, England)|May 10, 2025
EXCALIBER-RRMM: a phase III trial of iberdomide, daratumumab, and dexamethasone in relapsed/refractory multiple myelomaSagar Lonial, Meletios A Dimopoulos, Jesus G Berdeja, et al.
Clinical Lymphoma, Myeloma & Leukemia|October 9, 2012
An open-label single-arm pilot phase II study (PX-171-003-A0) of low-dose, single-agent carfilzomib in patients with relapsed and refractory multiple myelomaSundar Jagannath, Ravi Vij, A Keith Stewart, et al.
Medrxiv : the Preprint Server for Health Sciences|March 18, 2024
The Majority of SARS-CoV-2 Plasma Cells are Excluded from the Bone Marrow Long-Lived Compartment 33 Months after mRNA VaccinationDoan C Nguyen, Ian T Hentenaar, Andrea Morrison-Porter, et al.
Pageof 44

Showing results (221-230 of 440) with videos related to

Sort By:
Pageof 44
Pharmacotherapy|February 5, 2022
Impact of concurrent gabapentin or pregabalin with high-dose melphalan in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplantAkhilesh Sivakumar, Evan B Bryson, Kevin H Hall, et al.
Leukemia|January 26, 2019
Functional profiling of venetoclax sensitivity can predict clinical response in multiple myelomaShannon M Matulis, Vikas A Gupta, Paola Neri, et al.
Leukemia & Lymphoma|February 1, 2012
Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myelomaJeffrey L Wolf, David Siegel, Hartmut Goldschmidt, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 15, 2013
Temporal changes in plerixafor administration and hematopoietic stem cell mobilization efficacy: results of a prospective clinical trial in multiple myelomaR Donald Harvey, Jonathan L Kaufman, Heather R Johnson, et al.
Cancer|October 18, 2018
Survival outcomes of patients with primary plasma cell leukemia (pPCL) treated with novel agentsRoberto Mina, Nisha S Joseph, Jonathan L Kaufman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 6, 2017
Ricolinostat, the First Selective Histone Deacetylase 6 Inhibitor, in Combination with Bortezomib and Dexamethasone for Relapsed or Refractory Multiple MyelomaDan T Vogl, Noopur Raje, Sundar Jagannath, et al.
Cancer Informatics|October 8, 2014
Integrated analysis of whole-genome paired-end and mate-pair sequencing data for identifying genomic structural variations in multiple myelomaRendong Yang, Li Chen, Scott Newman, et al.
Future Oncology (London, England)|May 10, 2025
EXCALIBER-RRMM: a phase III trial of iberdomide, daratumumab, and dexamethasone in relapsed/refractory multiple myelomaSagar Lonial, Meletios A Dimopoulos, Jesus G Berdeja, et al.
Clinical Lymphoma, Myeloma & Leukemia|October 9, 2012
An open-label single-arm pilot phase II study (PX-171-003-A0) of low-dose, single-agent carfilzomib in patients with relapsed and refractory multiple myelomaSundar Jagannath, Ravi Vij, A Keith Stewart, et al.
Medrxiv : the Preprint Server for Health Sciences|March 18, 2024
The Majority of SARS-CoV-2 Plasma Cells are Excluded from the Bone Marrow Long-Lived Compartment 33 Months after mRNA VaccinationDoan C Nguyen, Ian T Hentenaar, Andrea Morrison-Porter, et al.
Pageof 44